SEC Form 4 · accession 0000899243-17-000669
KERYX BIOPHARMACEUTICALS INC · KERX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Greg Madison
Officer — President and CEO · Director
Period of report
Jan 5, 2017
Accepted (ET)
Jan 6, 2017 · 4:05 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001114220
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jan 5, 2017 | S | 1,077 | $6.16 | D | 253,570 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Sale of a total of 1,077 shares of common stock was made in order to satisfy Mr. Madison's income tax withholding obligation upon the vesting of 2,823 shares of restricted stock on January 4, 2017. Mr. Madison had no discretion with respect to such sale, which was transacted automatically in accordance with the Issuer's corporate policies regarding the vesting of restricted stock.
- F2Includes 170,041 shares of restricted stock.